Regulation of MMP 2 and MMP 9 expressions modulated by AP-1 (c-jun) in wound healing: improving role of Lucilia sericata in diabetic rats
- 150 Downloads
Lucilia sericata larvae have been successfully used on healing of wounds in the diabetics. However, the involvement of the extraction/secretion (ES) products of larvae in the treatment of diabetic wounds is still unknown. Activator protein-1 (AP-1) transcription, composed of c-jun and c-Fos proteins, has been shown to be the principal regulator of multiple MMP transcriptions under a variety of conditions, also in diabetic wounds. Specifically, MMP-2 and MMP-9’s transcriptions are known to be modulated by AP-1. c-jun has been demonstrated to be a repressor of p53 in immortalized fibroblasts. The aim of the present study is to investigate the effects of L. sericata ES on the expression of AP-1 (c-jun), p53, MMP-2, and MMP-9 in wound biopsies dissected from streptozotocin induced diabetic rats.
The expression levels of MMP-2, MMP-9, c-jun and p53 in dermal tissues were determined at days 0, 3, 7 and 14 after wounding, using immunohistochemical analysis and quantitative real-time PCR.
The treatment with ES significantly decreased through inflammation-based induction of MMP-2 and MMP-9 expression levels in the wounds of diabetic groups, compared to control groups at the third day of wound healing. At the 14th day, there were dramatic decreases in expression of c-jun, MMP-9, and p53 in ES-treated groups, compared to the diabetic group (P < 0.001, P < 0.05 and P < 0.01, respectively).
ES products of L. sericata may enhance the process of wound healing in phases of inflammation, proliferation, and re-epithelization, essentially via regulating c-jun expression and modulating MMP-2 and MMP-9 expressions.
KeywordsSTZ diabetes Maggot debridement therapy Lucilia sericata MMP P53 AP-1
The concept and design of research belong to FKT and GSK. Animal experiments were carried out by FKT and MT, ES preparation by FKT, EP, and SS, RT-PCR was conducted by FKT and EC. TS and EYS carried out the immunohistochemical analysis. FKT, TS, and EYS performed data analysis, interpretation and writing the article, supervised by GSK. This work was supported by the Scientific Research Project Coordination Unit of Istanbul University (Project number: 35048).
Compliance with ethical standards
Conflict of interest
All authors stated that there is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.
Ethical standard statement
All procedures performed in studies involving animals were in accordance with the ethical standards of the Animal Ethical Committee of Istanbul University (Approval no. 2013/39).
For this type of study, formal consent is not required.
- 3.Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825(1):29–36Google Scholar
- 4.Salo T, Mäkelä M, Kylmäniemi M, Autio-Harmainen H, Larjava H (1994) Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Investig J Tech Methods Pathol 70(2):176–182Google Scholar
- 7.Sato H, Seiki M (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8(2):395–405Google Scholar
- 9.Fini ME, Bartlett JD, Matsubara M et al (1994) The rabbit gene for 92-kDa matrix metalloproteinase. Role of AP1 and AP2 in cell type-specific transcription. J Biol Chem 269(46):28620–28628Google Scholar
- 10.Yokoo T, Kitamura M (1996) Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 270(1 Pt 2):F123–F130Google Scholar
- 12.Knaś M, Niczyporuk M, Zalewska A, Car H (2013) The unwounded skin remodeling in animal models of diabetes types 1 and 2. Physiol Res 62(5):519–526. (Epub 2013 Sep 10) Google Scholar
- 28.Shiau MY, Tsai ST, Tsai KJ, Haung ML, Hsu YT, Chang YH (2006) Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med 73(7):1024–1028Google Scholar
- 30.Wu SC, Driver VR, Wrobel JS, Armstrong DG (2007) Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag 3:65–76Google Scholar